Posts

Pharma deal headlines: AstraZeneca backs ivonescimab, Novo licenses Hengrui’s obesity candidate

on
****AstraZeneca–ivonescimab:** ** AstraZeneca is making a reported $2 billion investment in Summit Therapeutics to support development of ivonescimab, a PD-1/VEGF bispecific antibody, in combinations with AstraZeneca’s antibody-drug conjugates across cancer types. The reported investment would give AstraZeneca a substantial minority stake in Summit; it is an investment, not an acquisition of the drug. ****Novo Nordisk–Hengrui:** ** Novo agreed to license rights outside mainland China, Hong Kong, Macao and Taiwan to Hengrui’s experimental candidate HRS-1596 , in a deal worth up to $2.6 billion . That includes $300 million upfront , potential development, regulatory and commercial milestones, and royalties. The GLP-1/GIP drug is Phase 1-ready and has potential for once-weekly oral dosing, but it remains early-stage. ** Merck and KRAS: ** The headline refers to Merck’s continued push into KRAS-targeted cancer treatments. The available search results here did not provide reliable d...

Novartis strikes potential $7.8 billion Abogen deal for in vivo autoimmune therapy

on

Regeneron plans obesity-drug and cholesterol-therapy combination

on

Ultragenyx’s MPS IIIA Gene Therapy Application Validated by EMA

on

Talus Bio’s Ptarmigan-1 aims to find drug targets without protein structures

on

Foghorn cuts 40% of staff after ending Lilly cancer programs

on

BMS fibrosis-trial death raises liver-safety questions, but cause remains uncertain

on

CMS finalizes GLOBE model to link some Part B drug rebates to international prices

on

Varda raises $251 million to scale pharmaceutical processing in space

on

Lilly’s amylin–Zepbound combination shows up to 23.3% weight loss

on

Mironid begins dosing in first-in-human ADPKD drug trial

on

Merck’s anti-TL1A drug shows promising Phase 2b results in hidradenitis suppurativa

on

Ceribell wins FDA clearance for new EEG trending and analysis features

on